Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Emma J. Seaber"'
Autor:
John Allanson, Deborah A. Smith, Richard Peck, Nanco R. Hefting, Jan J. van Lier, Emma J. Seaber, Frans A. E. Sollie, Johan Wemer, Jan H. G. Jonkman
Publikováno v:
British Journal of Clinical Pharmacology. 46:433-439
Aims Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT1B/1D receptor agonist developed for the acute oral treatment of migraine. A highly sensitive LCMS-MS assay has been developed which allows quantification of plasma concentrations of zolmitri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e6deefe44da66cfe877a91e5a5f66b
https://doi.org/10.1046/j.1365-2125.1998.00809.x
https://doi.org/10.1046/j.1365-2125.1998.00809.x
Autor:
John Posner, Ruth M. Dixon, Barry C. Weatherley, Emma J. Seaber, Gary R. Layton, Richard W. Peck, Paul E. Rolan, Stephen D. Jackson
Publikováno v:
Clinical Pharmacology & Therapeutics. 63:342-353
Objective Zolmitriptan is a selective 5HT1B/1D-agonist for the treatment of migraine. In this study we investigated the cardiovascular and central nervous system effects and the pharmacokinetics of zolmitriptan in young and elderly adults. Methods Tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb485c3b7782f207ea805ec54fd5cdc
https://doi.org/10.1016/s0009-9236(98)90166-7
https://doi.org/10.1016/s0009-9236(98)90166-7
Publikováno v:
Clinical Drug Investigation. 14:221-225
This double-blind, randomised, two-period crossover study investigated the effect of pizotifen on the pharmacokinetics and tolerability profile of zolmitriptan (formerly 311C90), a novel selective 5-HT1D receptor agonist for acute migraine therapy. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9557b8770b0dbc9ce61205bbc5d5a6a2
https://doi.org/10.2165/00044011-199714030-00010
https://doi.org/10.2165/00044011-199714030-00010
Autor:
Ruth Dixon, John Posner, M. Gibbens, Emma J. Seaber, Richard Peck, Paul Rolan, N. On, W. J. Leavens, J. Liptrot, G. Chittick
Publikováno v:
British Journal of Clinical Pharmacology. 43:579-587
Aims Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of zolmitriptan (311C90), a novel 5HT1D agonist for the acute treatment of migraine. Methods After an initial test i.v. inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d19fa5ce675eb14feaa6873341ea3c
https://doi.org/10.1046/j.1365-2125.1997.00614.x
https://doi.org/10.1046/j.1365-2125.1997.00614.x
Publikováno v:
British Journal of Clinical Pharmacology. 41:141-147
1 311C90 is a novel and selective agonist at 5-HT1D receptors, with central and peripheral actions, currently in development for the acute oral treatment of migraine. 2 The pharmacokinetic and tolerability profiles of single oral doses from 1–50 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ceda635123036af3fe9cedee94caac
https://doi.org/10.1111/j.1365-2125.1996.tb00172.x
https://doi.org/10.1111/j.1365-2125.1996.tb00172.x
Autor:
C. Gillotin, John Posner, Emma J. Seaber, Ruth Dixon, Richard Peck, Gary Layton, Barry Weatherley
Aims Zolmitriptan (Zomig, formerly known as 311C90), a selective 5HT1B/1D agonist is under development as an acute oral treatment for migraine. Despite the use of prophylactic medication, such as propranolol, breakthrough attacks often occur in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5fc2810f3a6fcdb057e8a691152ce0e
https://europepmc.org/articles/PMC2042889/
https://europepmc.org/articles/PMC2042889/
